Why 10x Genomics' Soaring Q4 Revenue Wasn't Enough to Impress Investors

If you want evidence that investors are excited about genetic testing stocks, just take a look at 10x Genomics (NASDAQ: TXG). Its shares skyrocketed 86% in 2020 and are up over 30% so far this year. 

10x Genomics announced its fourth-quarter and full-year 2020 results after the market close on Wednesday. The healthcare stock fell around 2.5% in after-hours trading. Here are the highlights from the company's Q4 update.

Image source: Getty Images.

Continue reading

Source Fool.com